SomaKit TOC is the first ever approved kit for preparation of a PET radiopharmaceutical.
After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases.
Gallium (68Ga) edotreotide binds to somatostatin receptors. In vitro, this radiopharmaceutical binds with high affinity mainly to SSTR2 but also, to a lesser extent, to SSTR5.
The kit reduce the preparation time substantially as well as the time for the quality control compared to production of Ga-68 Dotatoc.
SomaKit TOC was approved by the European Medicines Agency in December 2016 and was placed on the Scandinavian market the 1st of September 2017.
For more information see Summary of product characteristics (SmPC).